Scancell buddies up with 'new immuno-oncology powerhouse'

UK-based oncology specialist Scancell Holdings (LSE: SCLP) has announced a collaboration with Europe’s largest privately-held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases.

The collaboration will focus on the potential development of innovative, T-cell receptor based therapeutics for the treatment of cancer and combines Scancell’s Moditope immunotherapy platform and BioNTech’s technology for high-throughput cloning and characterization of naturally selected T-cell receptors.

"Our Moditope platform has shown unprecedented anti-tumor effects can be delivered without the need for checkpoint inhibition. We believe that this, combined with BioNTech’s engineered T-cells specific to Moditope epitopes, could have great potential"